Perspectives in therapy for hepatitis C

Expert Opinion on Investigational Drugs

Volumn 17, Issue 11, 2008, Pages 1635-1639

  Vento, Sandro ^a   Cainelli, Francesca ^a   Temesgen, Zelalem ^b  

^a ANNUNZIATA HOSPITAL   (Italy)

^b MAYO CLINIC   (United States)

Author keywords

Alb IFN; Antivirals; Boceprevir; Cyp inhibitors; Hepatitis C; Peg IFN; Polymerase inhibitors; Protease inhibitors; Ribavirin; Telaprevir

Indexed keywords

4' AZIDOCYTIDINE 2',3',5' TRIISOBUTYRATE; ALPHA INTERFERON; ANTIINFECTIVE AGENT; ANTIVIRUS AGENT; CILUPREVIR; CYCLOSPORIN A [4 N METHYLISOLEUCINE]; CYTOCHROME P450 INHIBITOR; DEBIO 025; N [3 AMINO 1 (CYCLOBUTYLMETHYL) 2,3 DIOXOPROPYL] 3 [2 (3 TERT BUTYLUREIDO) 3,3 DIMETHYL 1 OXOBUTYL] 6,6 DIMETHYL 3 AZABICYCLO[3.1.0]HEXANE 2 CARBOXAMIDE; NM 107; NUCLEOSIDE ANALOG; PEGINTERFERON; PEGINTERFERON ALPHA; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; PLACEBO; PROTEINASE INHIBITOR; R 7128; RECOMBINANT ALPHA2B INTERFERON; RECOMBINANT HUMAN SERUM ALBUMIN; RECOMBINANT HUMAN SERUM ALBUMIN PLUS INTERFERON; RECOMBINANT HUMAN SERUM ALBUMIN PLUS RECOMBINANT ALPHA2B INTERFERON; RIBAVIRIN; RNA DIRECTED DNA POLYMERASE INHIBITOR; TELAPREVIR; THIOPENE 2 CARBOXYLIC ACID; TMC 435350; UNCLASSIFIED DRUG; VIRUS RNA;

ABNORMAL LABORATORY RESULT; ANEMIA; ANTIVIRAL ACTIVITY; ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DRUG ERUPTION; DRUG HALF LIFE; DRUG POTENTIATION; DRUG SAFETY; DRUG TISSUE LEVEL; DRUG TOLERABILITY; DRUG WITHDRAWAL; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HYPERBILIRUBINEMIA; MONOTHERAPY; NAUSEA; NEUTROPENIA; NONHUMAN; PATIENT COMPLIANCE; PRURITUS; SIDE EFFECT; UNSPECIFIED SIDE EFFECT; VIRUS INHIBITION; VIRUS STRAIN;

ANTIVIRAL AGENTS; CLINICAL TRIALS AS TOPIC; CYTOCHROME P-450 ENZYME SYSTEM; ENZYME INHIBITORS; HEPATITIS C; HUMANS; VIRAL NONSTRUCTURAL PROTEINS;

EID: 54949154193     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.17.11.1635     Document Type: Article

References (19)

1. Reesink HW, Zeuzem S, Weegink CJ, et al. Rapid decline of viral RNA in hepatitis C patients treated with VX-950: a Phase 1b, placebo controlled, randomized study. Gastroenterology 2006;131:997-1002
2. Forestier N, Reesink HW, Weegink CJ, et al. Antiviral activity of telaprevir (VX-950) and peginterferon alfa-2a in patients with hepatitis C. Hepatology 2007;46:640-8
3. Lawitz E, Rodriguez-Torres M, Muir AJ, et al. Antiviral effects and safety of telaprevir, peginterferon alfa-2a, and ribavirin for 28 days in hepatitis C patients. J Hepatol 2008;49:163-9
4. McHutchison JG, Everson GT, Gordon SC, et al. PROVE1: results from a Phase 2 study of telaprevir with peginterferon alfa-2a and ribavirin in treatment-naive subjects with hepatitis C [abstract 4]. J Hepatol 2008;48:S4
5. Dusheiko GM, Hézode C, Pol S, et al. Treatment of chronic hepatitis C with telaprevir in combination with peginterferon alfa-2a with or without ribavirin: interim results of the PROVE2 study [abstract 58]. J Hepatol 2008;48:S26
6. Kwo P, Lawitz E, McCone J, et al. Interim results from HCV SPRiNT-1: RVR/ EVR from Phase 2 study of Boceprevir plus Pegintron (Peginterferon alfa-2b)/ribavirin in treatment naïve subjects with genotype-1 CHC [abstract 995]. J Hepatol 2008;48:S372
7. Simmen K, Lenz O, Lin TL, et al. In vitro activity and preclinical pharmacokinetics of the HCV protease inhibitor, TMC435350 [abstract 1390]. Hepatology 2007;46(Suppl 1):857A
8. Reesink H, Verloes R, Abou Farha K, et al. Safety of the HCV protease inhibitor TMC435350 in healthy volunteers and safety and activity in chronic hepatitis C infected individuals: a Phase 1 study [abstract 64]. J Hepatol 2008;48:S28
9. Pockros PJ, Nelson D, Godofsky E, et al. R1626 plus peginterferon alfa-2a provides potent suppression of hepatitis C virus RNA and signifi cant antiviral synergy in combination with ribavirin. Hepatology 2008;48:385-97
10. Nelson D, Pockros PJ, Godofsky E, et al. High end-of-treatment response (84%) after 4 weeks of R1626, peginterferon alfa-2a (40KD) and ribavirin followed by a further 44 weeks of peginterferon alfa-2a and ribavirin [abstract 993]. J Hepatol 2008;48:S371
11. Lalezari J, Gane E, Rodriguez-Torres M, et al. Potent antiviral activity of the HCV nucleoside polymerase inhibitor R7128 with peg-IFN and ribavirin: interim results of R7128 500 mg bid for 28 days [abstract 66]. J Hepatol 2008;48:S29
12. Flisiak R, Horban A, Gallay P, et al. The cyclophilin inhibitor Debio-025 shows potent anti-hepatitis C effect in patients coinfected with hepatitis C and human immunodeficiency virus. Hepatology 2008;47:817-26
13. Flisiak R, Feinman SV, Jablkowski M, et al. Efficacy and safety of increasing doses of the cyclophilin inhibitor Debio 025 in combination with pegylated interferon alpha-2a in treatment naïve chronic HCV patients [abstract 143]. J Hepatol 2008;48:S62
14. Zeuzem S, Yoshida EM, Benhamou Y, et al. Albinterferon alfa-2b dosed every two or four weeks in interferon-naive patients with genotype 1 chronic hepatitis C. Hepatology 2008;48:407-17
15. Zeuzem S, Buti M, Ferenci P, et al. Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia. J Hepatol 2006;44:97-103
16. Sarrazin C, Kieffer TL, Bartels D, et al. Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir. Gastroenterology 2007;132:1767-77
17. Kuntzen T, Timm J, Berical A, et al. Naturally occurring dominant resistance mutations to HCV protease and polymerase inhibitors in treatment-naïve patients. Hepatology 2008 (doi:10.1002/hep.22549)
18. Grünberger C, Wyles DL, Kaihara KA, Schooley RT. 3-Drug synergistic interactions of small molecular inhibitors of hepatitis C virus replication. J Infect Dis 2008;197:42-5
19. Mathy JE, Ma S, Compton T, Lin K. Combinations of a cyclophilin inhibitor NIM811 with HCV NS3-4A protease or NS5B polymerase inhibitors enhance antiviral activity and suppress the emergence of resistance. Antimicrob Agents Chemother 2008 (doi: 10.1128/AAC.00498-08)